Samchundang Pharmaceutical Begins First Export of Generic Eye Drops
[Asia Economy Reporter Jang Hyowon] Samchundang Pharmaceutical announced on the 18th that it has made its first export related to a single-use glaucoma treatment contracted with its European partner, OMNIVISION.
Samchundang Pharmaceutical expects regular exports to be made every 1 to 2 months following this first shipment. In particular, as demand for single-use glaucoma treatments is increasing in Europe, the volume of future exports is expected to continue to grow.
In 2018, Samchundang Pharmaceutical signed an export contract for single-use glaucoma treatments. At the time of the contract, the expected annual sales were 10 billion KRW, but considering the recent surge in market demand, it is now predicted to be around 20 billion KRW, which accounts for approximately 20% of Samchundang Pharmaceutical's sales.
Hot Picks Today
"You Might Regret Not Buying Now"... Overseas Retail Investors Stirred by News of Record-Breaking Monster Stocks' IPOs
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Mistaken for the Flu, Left Untreated... Death Toll Surges as WHO Declares Emergency (Comprehensive)
- Takaichi Says, "I Was Debating Drinking Due to Parliament Schedule"... President Lee Jokes, "Should I Make a Call?"
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
A representative from Samchundang Pharmaceutical stated, “We are making every effort to achieve visible results within the year for other ongoing projects besides generic eye drops.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
